### Saturday, June 2, 2007

**7:30 AM - 10:30 AM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM - 7:45 AM</td>
<td>Melanoma</td>
<td>EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. <strong>Abstract No: 8504</strong>&lt;br&gt;Presenter: Alexander M Eggermont, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>8:15 AM - 8:30 AM</td>
<td>Melanoma</td>
<td>Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs). <strong>Abstract No: 8507</strong>&lt;br&gt;Presenter: Marna Bouwhuis</td>
<td></td>
</tr>
<tr>
<td>9:00 AM - 9:15 AM</td>
<td>Melanoma</td>
<td>Long-term protective effect of mature DC-LAMP⁺ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. <strong>Abstract No: 8509</strong>&lt;br&gt;Presenter: Richard A Scolyer, MD</td>
<td></td>
</tr>
</tbody>
</table>

**9:30 AM - 12:00 PM**

**Opening Session and Special Awards, including Karnofsky Memorial Award and Lecture**

**2:00 PM - 6:00 PM**

**3:00 PM - 6:15 PM**

**Sunday, June 3, 2007**

**8:00 AM - 12:00 PM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Central Nervous System Tumors</td>
<td>EORTC Study 26041-22041: Phase II/III study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma–Results of a phase I trial. <strong>Poster Number: 14 Abstract No: 2026</strong>&lt;br&gt;Presenter: Alba A Brandes</td>
<td></td>
</tr>
</tbody>
</table>

**8:00 AM**

**Developmental Therapeutics: Cytotoxic Chemotherapy**
12:00 PM  
S Hall A2  
- Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: Results from randomized EORTC 05011 trial.

Poster Number: C8  
Abstract No: 2566  
Presenter: Carlo Garufi, MD

9:30 AM - 12:30 PM  
E Hall D2  
- Genitourinary Cancer (Testes, Kidney and Bladder)  
  - 11:45 AM - 12:00 PM  
    Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study.

Abstract No: LBA5030  
Presenter: Joaquim Bellmunt, MD

11:00 AM - 12:00 PM  
S100a  
- Central Nervous System Tumors  
  - EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma--Results of a phase I trial.

Poster Number: 14  
Abstract No: 2026  
Presenter: Alba A Brandes

1:00 PM - 4:00 PM  
S100a  
- Central Nervous System Tumors  
  - 1:15 PM – 1:30 PM  
    Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034.

Abstract No: 2005  
Presenter: Martin J Van Den Bent, MD

2:00 PM - 5:00 PM  
N Hall B1  
- Lung Cancer II  
  - 2:00 PM – 2:15 PM  
    Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): First results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial.

Abstract No: 7518  
Presenter: Marianne Nicolson

2:00 PM - 6:00 PM  
S Hall A2  
- Melanoma  
  - LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: Re-analysis of GM301 and EORTC18951 randomized trials.

Poster Number: Q4  
Abstract No: 8552  
Presenter: Ulrich Keilholz, MD

Monday, June 4, 2007

7:30 AM - 10:45 AM  
E354b  
- Sarcoma  
  - 7:30 AM - 7:45 AM  
    Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial.

Abstract No: 10008  
Presenter: Penella J Woll, MD, PhD

  - 7:45 AM - 8:00 AM  
    Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall
and the abdomen: A phase III randomised pros.

**Abstract No: 10009**
Presenter: Rolf D Issels, MD, PhD

8:00 AM - 12:00 PM  
S Hall A2  
Gastrointestinal (Colorectal) Cancer  
- A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029.

Poster Number: H3  
**Abstract No: 4090**  
Presenter: Denis A Lacombe, MD

9:30 AM - 12:30 PM  
E Arie Crown Theater  
Genitourinary Cancer (Prostate and Testes)  
- 9:30 AM - 9:45 AM  
Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC Phase III trial 22961.

**Abstract No: 5014**  
Presenter: Michel Bolla, MD

1:00 PM - 4:00 PM  
N Hall B1  
Monday Plenary Session  
- 3:00 PM - 3:15 PM  
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993).

**Abstract No: 4**  
Presenter: Ben Slotman, MD, PhD

- 3:30 PM - 3:45 PM  
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases.

**Abstract No: LBA5**  
Presenter: Bernard Nordlinger, MD

2:00 PM - 6:00 PM  
S102a  
Developmental Therapeutics: Cytotoxic Chemotherapy  
- 5:00 PM - 6:00 PM  
Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG.

**Poster Number: 22  
Abstract No: 2529**  
Presenter: Markus Joerger, MD

2:00 PM - 6:00 PM  
S103a  
Sarcoma  
- Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043.

**Poster Number: 15  
Abstract No: 10031**  
Presenter: Stefan Sleijfer, MD, PhD

5:00 PM - 6:00 PM  
S404  
Sarcoma  
- Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043.

**Poster Number: 15  
Abstract No: 10031**  
Presenter: Stefan Sleijfer, MD, PhD

**Tuesday, June 5, 2007**

7:30 AM - 9:00 AM  
S100b  
Practical Management of Gastrointestinal Stromal Tumors, 2007  
- 7:30 AM - 7:45 AM  
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts).
Abstract No: 10004  
Presenter: Martine M Van Glabbeke, PhD  
8:00 AM - 12:00 PM  
S103a &  
11:00 AM - 12:00 PM  
S504  
Melanoma  
Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNα versus observation.  
Poster Number: 7 Abstract No: 8518  
Presenter: Stefan Suciu, PhD  
• Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study.  
Poster Number: 8 Abstract No: 8519  
Presenter: Alain Spatz, MD  
• Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials.  
Poster Number: 15 Abstract No: 8526  
Presenter: Keith Wheatley, D.Phil  

Session Types

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Sessions</td>
<td>Include Award Lectures as well as symposia recommended by other oncology-related organizations (and developed in conjunction with ASCO), the Cancer Education Committee, the Scientific Program Committee, and the ASCO Board of Directors, as being of particular interest, importance, and relevance to Meeting attendees.</td>
</tr>
<tr>
<td>Clinical Science Symposia</td>
<td>Formerly known as Integrated Education Sessions, these sessions provide a forum for science in oncology, combining the presentation of selected abstracts on a specific topic with didactic lectures. Experts in the field place the studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.</td>
</tr>
<tr>
<td>Oral Abstract Presentation Sessions</td>
<td>Include didactic presentations of the abstracts determined by the Scientific Program Committee to be of the highest scientific merit. Experts in the field serve as Discussants to place the findings into perspective. The Plenary Session includes the abstracts selected by the Scientific Program Committee as having practice-changing findings.</td>
</tr>
<tr>
<td>Poster Discussion Sessions</td>
<td>Highlight selected abstracts of clinical research in poster format. The posters are grouped by topic or by the questions posed as a result of the research findings. The posters are on display for a specified time, followed by a discussion session in which experts provide commentary on the research findings.</td>
</tr>
<tr>
<td>General Poster Sessions</td>
<td>Include selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time.</td>
</tr>
</tbody>
</table>